|
Re: Some more reading material
|
3
|
Resverlogix Corp.
|
May 01, 2020 08:12PM
|
|
Re: Shorts
|
3
|
Resverlogix Corp.
|
Apr 26, 2021 03:12PM
|
|
Re: Shawn lu RSU and option cancelled
|
5
|
Resverlogix Corp.
|
Apr 07, 2020 11:38AM
|
|
Re: Shawn lu RSU and option cancelled
|
5
|
Resverlogix Corp.
|
Apr 07, 2020 01:21PM
|
|
Re: Shawn lu RSU and option cancelled
|
5
|
Resverlogix Corp.
|
Apr 07, 2020 02:38PM
|
|
Re: Saudi
|
5
|
Resverlogix Corp.
|
Apr 07, 2021 03:10PM
|
|
Re: RVX Market Value
|
4
|
Resverlogix Corp.
|
Jan 28, 2021 06:07PM
|
|
Re: RVX Announces Update Webcast and Conference Call
|
2
|
Resverlogix Corp.
|
Jan 18, 2021 07:51AM
|
|
Re: Revised target market, indications, market potential? ... and some numbers?
|
5
|
Resverlogix Corp.
|
Jun 13, 2020 10:26AM
|
|
Re: Revised target market, indications, market potential? ... and some numbers - RVXOT
|
2
|
Resverlogix Corp.
|
Jun 13, 2020 05:03PM
|
|
Re: Resverlogix Secures One-Year Extension of Maturity Date of Debenture
|
6
|
Resverlogix Corp.
|
Jul 22, 2020 11:28AM
|
|
Re: Resverlogix Reschedules Update Webcast and Conference Call: Now February 4th 10AM MT
|
7
|
Resverlogix Corp.
|
Jan 27, 2021 06:45PM
|
|
Re: Resverlogix Reports Filing of New Intellectual Property - question
|
3
|
Resverlogix Corp.
|
Nov 02, 2020 12:49PM
|
|
Re: Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study
|
10
|
Resverlogix Corp.
|
Jun 22, 2020 10:42PM
|
|
Re: Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study
|
5
|
Resverlogix Corp.
|
Jun 22, 2020 08:50AM
|
|
Re: RESVERLOGIX CORP WTS 2021
|
1
|
Resverlogix Corp.
|
May 11, 2021 05:21PM
|
|
Re: Resverlogix Confirms Interim Filings on SEDAR
|
8
|
Resverlogix Corp.
|
Oct 03, 2020 03:02PM
|
|
Re: Resverlogix Confirms Interim Filings on SEDAR
|
6
|
Resverlogix Corp.
|
Oct 04, 2020 12:48PM
|
|
Re: Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication - Derek Lowe
|
4
|
Resverlogix Corp.
|
Mar 26, 2020 06:14PM
|
|
Re: Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication
|
6
|
Resverlogix Corp.
|
Mar 26, 2020 08:47AM
|
